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glycated hemoglobin (HbA1c) testing, annual eye examination, kidney function examination, and low-
density lipoprotein (LDL) testing in patients below 75 years. We aimed to describe regional variation in
the utilization of the four measures across small regions in Switzerland and to explore potential influencing
factors. RESEARCH DESIGN AND METHODS We conducted a cross-sectional study of adult patients
with drug-treated diabetes in 2014 using claims data. Four binary outcomes represented adherence to the
recommendations. Possible influencing factors included sociodemographics, health insurance preferences,
and clinical characteristics. We performed multilevel modeling with Medstat regions as the higher level.
We calculated the median odds ratio (MOR) and checked spatial autocorrelation in region level residuals
using Moran’s I statistic. When significant, we further conducted spatial multilevel modeling. RESULTS
Of 49 198 patients with diabetes (33 957 below 75 years), 69.6% had biannual HbA1c testing, 44.3%
each had annual eye examination and kidney function examination, and 55.5% of the patients below
75 years had annual LDL testing. The effects of health insurance preferences were substantial and
consistent. Having any supplementary insurance (ORs across measures were between 1.08 and 1.28),
having supplementary hospital care insurance (1.08-1.30), having chosen a lower deductible level (eg,
SFr2500 compared with SFr300: 0.57-0.69), and having chosen a managed care model (1.04-1.17) were
positively associated with recommendations adherence. The MORs (1.27-1.33) showed only moderate
unexplained variation, and we observed inconsistent spatial patterns of unexplained variation across the
four measures. CONCLUSION Our findings indicate that the uptake of strongly recommended measures
in diabetes management could possibly be optimized by providing further incentives to patients and care
providers through insurance scheme design. The absence of marked regional variation implies limited
potential for improvement by targeted regional intervention, while provider-specific promotion may be
more impactful.
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Significance of this study
What is already known about this subject?
 ► Better adherence to clinical guidelines and recom-
mendations could increase clinical outcomes of pa-
tients with diabetes.
 ► Little is known about the utilization and its region-
al variation of recommended measures in diabetes 
management.
What are the new findings?
 ► In a healthcare system with mandatory health insur-
ance, choosing a lower deductible level, choosing 
a managed care model, and having supplementary 
insurance were associated with better adherence.
 ► Unexplained variation after adjusting for possible in-
fluencing factors was not pronounced, and inconsis-
tent spatial patterns were observed across different 
measures.
How might these results change the focus of 
research or clinical practice?
 ► The findings imply a potential to optimize the utili-
zation of recommended healthcare services by pro-
viding further incentives through insurance scheme 
design.
ABSTRACT
Introduction Four strongly recommended diabetes 
management measures are biannual glycated hemoglobin 
(HbA1c) testing, annual eye examination, kidney function 
examination, and low- density lipoprotein (LDL) testing in 
patients below 75 years. We aimed to describe regional 
variation in the utilization of the four measures across 
small regions in Switzerland and to explore potential 
influencing factors.
Research design and methods We conducted a 
cross- sectional study of adult patients with drug- 
treated diabetes in 2014 using claims data. Four 
binary outcomes represented adherence to the 
recommendations. Possible influencing factors included 
sociodemographics, health insurance preferences, 
and clinical characteristics. We performed multilevel 
modeling with Medstat regions as the higher level. We 
calculated the median odds ratio (MOR) and checked 
spatial autocorrelation in region level residuals using 
Moran’s I statistic. When significant, we further 
conducted spatial multilevel modeling.
Results Of 49 198 patients with diabetes (33 957 below 
75 years), 69.6% had biannual HbA1c testing, 44.3% 
each had annual eye examination and kidney function 
examination, and 55.5% of the patients below 75 years 
had annual LDL testing. The effects of health insurance 
preferences were substantial and consistent. Having 
any supplementary insurance (ORs across measures 
were between 1.08 and 1.28), having supplementary 
hospital care insurance (1.08–1.30), having chosen 
a lower deductible level (eg, SFr2500 compared with 
SFr300: 0.57–0.69), and having chosen a managed 
care model (1.04–1.17) were positively associated with 
recommendations adherence. The MORs (1.27–1.33) 
showed only moderate unexplained variation, and we 
observed inconsistent spatial patterns of unexplained 
variation across the four measures.
Conclusion Our findings indicate that the uptake of 
strongly recommended measures in diabetes management 
could possibly be optimized by providing further incentives 
to patients and care providers through insurance scheme 
design. The absence of marked regional variation implies 
limited potential for improvement by targeted regional 
intervention, while provider- specific promotion may be 
more impactful.
InTRoduCTIon
Diabetes is one of the most common chronic 
diseases. The global prevalence in adults over 
18 years was 8.5% (around 422 million) in 
2014, and deaths directly caused by diabetes 
were estimated at 1.6 million in 2016.1 In 
Switzerland, an estimated 500 000 persons 
suffer from the condition, which is respon-
sible for around 2% of all deaths.2 Diabetes 
can be treated and its complications delayed 
through various measures, including constant 
medical care, restricted diet, physical activity, 
and regular screening.3
A variety of clinical guidelines on diabetes 
management have been developed nationally 
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and internationally to improve outcomes. The Swiss 
Society of Endocrinology and Diabetology (SGED) has 
developed “The criteria for good disease management 
of Diabetes in primary care” in 2013 and revised it in 
2017.4 The American Diabetes Association, the European 
Society of Cardiology, and the European Association for 
the Study of Diabetes report and annually adapt clinical 
guidelines on diabetes as well.5 6 Some recommendations 
on diabetes management are crucial and consistently 
present in almost all clinical guidelines, for instance, bian-
nual glycated hemoglobin (HbA1c) testing, annual eye 
examination, and low- density lipoprotein (LDL) testing. 
Studies have shown strong evidence that the complica-
tions of diabetes could be reduced through managing 
risk factors such as increased HbA1c, LDLs, and blood 
pressure.7–9 It has also been reported that adherence to 
clinical guidelines had a positive influence on clinical 
outcomes including mortality and hospitalizations.10–12
In the present study, we used four strong standard 
recommendations included in most diabetes clinical 
guidelines, that is, patients with diabetes should undergo 
(1) at least two HbA1c tests per year, (2) at least one eye 
examination per year, (3) at least one kidney function 
examination per year, and (4) at least one LDL test per 
year (only in patients below 75 years). One study in Swit-
zerland using health insurance claims data for the years 
2011–2013 reported overall adherence to these recom-
mendations but did not perform an in- depth assessment 
of drivers of utilization or geographic variation.13 Gener-
ally, few studies have investigated the adherence to clin-
ical recommendations on diabetes management.
Various factors may affect the utilization of healthcare 
services for diabetes, including characteristics of patients, 
healthcare providers, health insurance, and regions. 
This could result in geographic variation in utilization. 
Such variation in utilization may be unwarranted, which 
would to some extent reflect unequal access.14 The four 
diabetes recommendations are clear and based on high- 
quality evidence, and the corresponding management 
measures are not preference sensitive.15 Moreover, access 
to healthcare in general and the four measures in partic-
ular is very good in Switzerland. Therefore, we expected 
little unexplained variation after adjusting for possible 
influencing factors in the present case.16
The aims of this study were to (1) investigate the utili-
zation levels of the above- defined strongly recommended 
measure in diabetes management, (2) explore potential 
factors influencing utilization, and (3) assess the regional 




We used health insurance claims data provided by the 
Helsana Group, one of the largest health insurance 
companies in Switzerland. The Helsana database under-
lying this study included mandatory health insurance 
claims from around 1.2 million people, covering 15% 
of the Swiss population. Adults (older than 18 years) 
enrolled with Helsana who were prescribed any diabetes 
medication (the Anatomical Therapeutic Chem-
ical code was used to identify diabetes medications) 
between January 1, 2014 and December 27, 2014 were 
analyzed. We excluded enrollees with incomplete insur-
ance coverage in 2014 or not surviving until the end of 
2014, patients living outside Switzerland, asylum seekers, 
Helsana employees, patients with incomplete address 
information, and patients living in nursing homes with 
lump- sum reimbursement. Since diagnosis information 
was not available for outpatient services, we could not 
distinguish between type 1 and type 2 diabetes.
Basic health insurance (covering a federally defined 
benefit package) is mandatory in Switzerland and 
private insurance companies are obliged to offer it to 
anyone irrespective of their health status. Mandatory 
health insurance includes appropriate and cost- effective 
inpatient and outpatient health services. A variety of 
annual deductibles (300–2500 Swiss Francs (SFr)) can 
be chosen, and selecting a higher deductible leads to a 
lower premium. Enrollees can also choose between stan-
dard and managed care models, where the latter require 
a specific general practitioner or telemedicine provider 
as the first contact when a new health problem arises, 
hence are cheaper.17 18 In addition to mandatory health 
insurance, a variety of supplementary health insurance 
products can be bought, for instance, supplementary 
hospital care insurance which allows for hospitalization 
in semiprivate/private wards.17
outcome and explanatory variables
We differentiated the participants according to whether 
they received diabetes medication between January 5, 
2013 and December 31, 2013 (prevalent cases if they 
received it, incident cases if they did not). The date of 
the first prescription of any diabetes medication in 2014 
(incident cases) or January 1, 2014 (prevalent cases) 
was considered as the index date for each participant. 
The following 360 days were regarded as the assessment 
period, which was used to define if the recommendations 
were being adhered to.
We defined binary outcome variables for the four 
measures under study: in the assessment period, (1) at 
least two HbA1c tests, (2) at least one eye examination 
(ophthalmologist visit was used as a proxy of eye exam-
ination), (3) at least one kidney function examination 
(ie, serum creatinine and/or albuminuria test), and (4) 
at least one LDL test (or total cholesterol+high- density 
lipoprotein (HDL)+triglycerides test) for patients below 
75 years.19
The explanatory variables included (1) sociode-
mographics, including age, gender, language region, 
purchasing power index per household, and urban/rural 
residence; (2) health insurance preferences, including 
having both mandatory and supplementary insurance, 
having supplementary hospital care insurance, standard 
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or managed care model, and choice of annual deduct-
ible; and (3) clinical characteristics, including number of 
comorbidities (pharmaceutical cost groups were used to 
deduce chronic morbidity based on drug use)20 and inci-
dent or prevalent diabetes treated with oral medication 
or insulin. In addition, a region- level variable—ophthal-
mologist density per 10 000 inhabitants—was used specif-
ically for the study of eye examinations.
Geographic unit
We used Medstat regions as the geographic units for 
regional variation analysis. Medstat regions (n=705) are 
defined by the Swiss Federal Statistical Office to reflect 
hospital catchment areas in a way that they are large 
enough to provide anonymity for each person hospi-
talized in Switzerland.21 Each patient’s residence was 
assigned to the corresponding Medstat region in the 
claims data.
statistical analysis
First, we performed a descriptive analysis of study popu-
lation’s characteristics. We distinguished between all 
eligible patients and the subpopulation below 75 years, 
relevant for the assessment of LDL testing.
Second, we mapped out the raw utilization rates of 
the four measures across Medstat regions to show their 
geographic distribution. We checked spatial autocorrela-
tion of regional utilization rates by computing the global 
Moran’s I statistic.22 Moran’s I measures the correlation 
of a variable with itself through space, with a value range 
from −1 to 1. Moran’s I values very close to 0 suggest the 
studied variable is randomly distributed through space. 
If Moran’s I is positive with p value <0.05, it indicates 
that neighboring regions are more similar than distant 
regions, and vice versa if Moran’s I is negative with p 
value <0.05.
Third, we performed multilevel multivariable logistic 
regression for each measure, with patients as the lower- 
level units and Medstat regions as the higher- level 
units. Decisions on inclusion of explanatory variables 
were based on the deviance information criterion.23 
We included age as a quadratic term to allow for non- 
linear relationships. The Medstat region- level variable 
of ophthalmologist density per 10 000 inhabitants was 
included in the model for eye examination. To esti-
mate the degree of random variation in the multilevel 
models, we calculated the median odds ratio (MOR) 
at the Medstat region level. The MOR compares the 
adjusted odds of being adherent to the recommendation 
in two patients with identical characteristics, but living 
in two randomly selected Medstat regions. It is defined 
as the median of all possible, resulting ORs. The MOR 
is never below one as the comparison is always between 
the higher- propensity region and the lower- propensity 
region, for the outcome of interest.24–26 A higher MOR 
indicates a higher level of unexplained variation in 
utilization after multivariable adjustment, and it can be 
compared directly with the ORs of the fixed effects.24–26 
We then checked for the presence of spatial autocorrela-
tion in the model residuals at the Medstat region level, 
for each measure.22
Finally, in cases with significant spatial autocorrelation 
present in the multilevel model residuals, we further 
developed Bayesian hierarchical logistic regression 
models capturing spatial variation at the Medstat region 
level through the Integrated Nested Laplace Approxima-
tions (INLA) approach.27–30 This was performed with the 
R- INLA package.31 The covariates included in the spatial 
multilevel models were the same as in the multilevel 
multivariable models above. The marginal effects of age 
divided into 50 groups were inspected graphically, which 
was more intuitive than reporting regression coeffi-
cients. The finally remaining geographic variation across 
Medstat regions was mapped out for each measure.
Statistical analyses were performed using R V.3.4.4,32 
STATA V.13, and MLwiN V.3.0433 integrated in STATA 
using the runmlwin package. Mapping was conducted 
with QGIS V.1.14.16,34 and spatial clustering analysis was 
done with GeoDa V.1.10.35
ResulTs
A total of 49 198 patients with diabetes were analyzed 
in this study. The mean age was 66.6 years, and women 
accounted for 45.0% of the whole study sample. Overall, 
34 254 (69.6%) patients had at least two HbA1c tests in 
their assessment period, 21 808 (44.3%) patients had 
at least one kidney function examination, and 21 804 
(44.3%) patients had at least one eye examination. 
Among the 49 198 patients with diabetes, 33 957 were 
below 75 years and were analyzed for LDL testing. In this 
subpopulation, 18 851 (55.5%) patients had at least one 
LDL test in the assessment period. The mean age was 60.1 
years, and 41.2% were women. Table 1 shows the socio-
demographics, health insurance preferences and clinical 
characteristics of the total population and of those below 
75 years, respectively.
The ORs and 95% confidence/credible intervals (95% 
CIs) of all explanatory variables (except age, shown in 
figure 1) in both the multilevel multivariable models and 
the spatial multilevel models are shown in figure 2 (full 
numerical details are available from online supplemen-
tary table S1 and S2). For each pair of models representing 
one outcome, covariate effects were similar, except for 
language region. Regarding sociodemographics, women 
were more likely to follow the recommendations of eye 
examination and kidney function examination, while 
the opposite was true for LDL testing. Purchasing power 
index was positively associated with eye examination and 
kidney function examination, while it was negatively asso-
ciated with HbA1c testing. Living in an urban area had 
a positive association with kidney function examination 
and LDL testing. Compared with the German- speaking 
area, living in the French or Italian speaking area of 
Switzerland demonstrated a negative association with 
HbA1c testing and eye examination, as well as positive 
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Figure 1 Age effect in spatial multilevel models. HbA1c, glycated hemoglobin; LDL, low- density lipoprotein.
associations with LDL testing and kidney function exam-
ination. As expected, these associations were strongly 
attenuated in the spatial multilevel models. The effects of 
health insurance preferences and clinical characteristics 
were mostly consistent across the four measures. Having 
any supplementary insurance (ORs across measures were 
between 1.08 and 1.28), having supplementary hospital 
care insurance (1.08–1.30), having chosen a managed 
care insurance model (1.04–1.17), and having more 
comorbidities (eg, having more than two morbidities 
compared with none: 1.25–1.57), were all positively asso-
ciated with being adherent to the recommendations. 
Having chosen a higher deductible level had a negative 
association with being adherent to the recommendations 
(eg, SFr2500 compared with SFr300: 0.57–0.69). Preva-
lent cases receiving insulin compared with incident cases 
had a positive association with HbA1c testing, eye exam-
ination and kidney function examination, while having a 
negative association with LDL testing. A positive associa-
tion between ophthalmologist density and eye examina-
tion was found in both models of eye examinations, with 
an OR of 1.13 in the spatial multilevel model.
The geographic distribution of the utilization of 
the four measures across Medstat regions is shown in 
figure 3. By visually inspecting the maps, we noted consid-
erable geographic variation for each measure, with quite 
different spatial patterns. For HbA1c testing, utilization 
rates were generally higher in the German- speaking 
north and middle part of Switzerland, while there was 
no such pattern visible for the other three measures. 
Positive and statistically significant (p<0.05) Moran’s I 
values of the raw rates indicating the presence of spatial 
autocorrelation were 0.46 for HbA1c testing, 0.27 for 
eye examination, 0.21 for kidney function examination, 
and 0.35 for LDL testing. After multilevel multivariable 
model adjustment, Moran’s I values of the residuals at 
the Medstat region level decreased to 0.12 (p<0.0001) 
for HbA1c testing, 0.13 (p=0.0001) for kidney function 
examination, and 0.07 (p=0.004) for LDL testing. Only 
for eye examination, we found a slight increase of spatial 
autocorrelation to 0.30 (p<0.001) after model adjust-
ments. In consequence, we regarded the spatial multi-
level models as most appropriate because they accounted 
for the spatial structure in the data. The MORs in the 
multilevel multivariable models, describing variation 
between Medstat regions, were 1.28 for HbA1c testing, 
1.31 for eye examination, 1.27 for kidney function exam-
ination, and 1.33 for LDL testing.
The unexplained spatial variation remaining after 
multivariable adjustment through spatial multilevel 
models for each measure is shown in figure 4. The OR 
values in figure 4 represent the odds of being adherent 
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Figure 2 ORs and 95% CIs of fixed effects in multilevel multivariable models and spatial multilevel models. CHF, Swiss 
franc; HbA1c, glycated hemoglobin; LDL, low- density lipoprotein; mc, managed care; mdt, mandatory insurance; Oph: 
ophthalmologist; Pchp, purchasing power; std, standard; sup, supplementary insurance; Suph insurance, supplementary 
hospital care insurance. Multimorbidity: pharmaceutical cost groups were used to deduce chronic morbidity based on drug 
use.
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Figure 3 Raw utilization rates of four diabetes management measures across 705 Medstat regions. HbA1c, glycated 
hemoglobin; LDL, low- density lipoprotein.
to the recommendation in one specific Medstat region 
compared with the average odds in the whole of Switzer-
land. We observed spatial clusters of better adherence in 
the northeast and middle parts of the country for HbA1c 
testing, in the north and east parts for eye examination, 
in the southwest and southeast parts for kidney function 
examination, and in the southwest part for LDL testing.
dIsCussIon
Observed utilization rates in 2014 in Switzerland of four 
strongly recommended measures in diabetes manage-
ment were 69.6% for biannual HbA1c testing, 44.3% for 
annual eye examination, 44.3% for annual kidney func-
tion examination, and 55.5% for annual LDL testing (in 
patients below 75 years). Associations between health 
insurance preferences and utilization were consistent 
across the four measures. Having supplementary insur-
ance, choosing a lower deductible level, and choosing 
a managed care insurance model were positively associ-
ated with being adherent to the recommendations. After 
adjusting for all available influencing factors and spatial 
autocorrelation, the unexplained regional variation was 
only moderate. There was no common pattern of spatial 
clustering visible across the four studied measures.
The observed utilization rates suggest that the under-
lying recommendations were not being followed 
perfectly. In a previous study using year 2011 to 2013 
data from the same data source, similar utilization rates 
were reported: 70.0% of patients had biannual HbA1c 
testing, 44.2% an annual eye examination, 12% both 
serum creatinine and albuminuria testing annually, and 
59.0% an annual lipid profile (total cholesterol, HDL 
and LDL, and triglycerides).13 The much higher rate of 
annual kidney function examination found in our study 
was mainly due to the use of a different definition of 
kidney function examination—a serum creatinine and/
or albuminuria test.
Overall, few studies assessing the utilization of manage-
ment measures recommended for diabetes patients 
exist, and some with discrepant findings. Some studies 
from the USA, Japan and Italy are directly comparable 
with ours as they reported on the utilization of at least 
one of our four measures of interest. For HbA1c testing, 
one study conducted in Texas, USA, reported a 54.8% 
biannual utilization rate,36 while the utilization rate in an 
Italian study was relatively low (33.9%).37 By contrast, a 
study from Japan using claims data found an annual utili-
zation rate of 95.8%.38 For eye examination, studies in 
the USA reported utilization rates of 15.3% (using claims 
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Figure 4 Unexplained variation in the utilization of four diabetes management measures in spatial multilevel models (OR 
values represent the odds of being adherent to the recommendation in one specific region compared with the average odds in 
the whole of Switzerland). HbA1c, glycated hemoglobin; LDL, low- density lipoprotein.
data),39 70% (using telephone survey data),40 and 75% 
(data from rural Latinos).41 A Japanese study reported 
a utilization rate of 35.6%,38 and the rate in the Italian 
study was even lower (15.6%).37 The Italian study also 
reported a utilization rate of LDL testing of 52.1%, which 
was similar to the finding in our study.37 However, these 
different reports may not be entirely comparable with 
our study since the data sources and definitions of adher-
ence to recommendations were different.
Patients’ sociodemographics were associated with 
healthcare utilization. The probability of undergoing the 
four recommended measures was generally high between 
age 50 and 80 years, and decreased strongly thereafter. 
This was expected because the elderly may have more 
barriers to accessing healthcare services due to poor 
health status. Moreover, the measures may become less 
important in the elderly as comorbidities and life expec-
tancy affect priority setting and the benefit of preventing 
long- term complications. Women were more likely to 
undergo eye examination and kidney function examina-
tion in our study, which was consistent with previous find-
ings.38 42 43 However, women were less likely to undergo 
annual LDL testing, which might be due to more atten-
tion to the risk of cardiovascular disease in men. Myocar-
dial infarction and related conditions have traditionally 
been perceived as predominantly male diseases. Living 
in an urban area was positively associated with more utili-
zation of annual kidney function examination and LDL 
testing, which may be partly explained by easier access 
to healthcare facilities than in rural areas. The language 
region effects on the utilization of the four measures 
found in the present study indicated that the language 
region plays an important role in influencing healthcare 
utilization, which might be due to different culture and 
norms in each language region.44 45
One of the key findings in the present study was the 
association between health insurance preferences and 
utilization of diabetes management measures, in a setting 
with mandatory insurance and universal access to care. 
Very few studies have explored the effect of health insur-
ance–related factors on services utilization in patients 
with diabetes. Most of the available studies only concluded 
that uninsured patients were less likely to use healthcare 
services than insured patients or patients with private 
insurance.36 40 While non- insurance does practically not 
occur in Switzerland, foregoing healthcare due to out- of- 
pocket payments is a well- documented phenomenon.46 
This is one of the first studies to look into potential influ-
ences of health insurance characteristics on utilization of 
measures on diabetes management in detail. Overall, we 
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found consistent effects of health insurance characteris-
tics on utilization across the four measures of interest, 
and they persisted after controlling for other important 
influences such as age, health status, and to some extent 
income (defined by regional purchasing power index). 
Patients with higher deductibles tend to be healthier 
and willing to take more risks, and some invoices may 
be missed in these patients, which may partially explain 
our observation of lower utilization of the measures of 
interest. However, higher out- of- pocket costs may also 
make patients more reluctant to use these measures, 
which would make high deductibles a financial barrier 
to recommended healthcare.47 Similarly, patients having 
supplementary insurance may be wealthier, and on 
average more health conscious. Thus, they may tend to 
seek care more frequently and regularly, as observed in 
our study. Patients choosing a managed care model had 
more utilization of the measures studied than patients 
choosing an insurance model offering completely free 
physician choice. This finding is of great interest because 
it may indicate that strengthening a coordinative role of 
primary care physicians in managed care and providing 
financial incentives to the insured for choosing such 
models may also positively impact certain healthcare 
utilization indicators or outcomes. More health insur-
ance incentives for participation in managed care models 
could be considered to achieve optimized healthcare 
utilization.
Presence of comorbidities was associated with more 
utilization, which may be due to more health aware-
ness and regular contact with healthcare providers. The 
finding of the lower uptake of LDL testing among prev-
alent cases was unexpected, as we would have expected 
prevalent patients to be more adherent to disease manage-
ment and treatment compared with new patients.48 The 
ophthalmologist density covariate reflected the access to 
eye examination services, and thus partly explained the 
higher utilization of eye examinations in patients living 
in regions with more ophthalmologists.
The unexplained geographic variation of utilization 
across small regions after adjusting for all available factors 
was only moderate for all four measures. One possible 
reason could be that we were unable to control for locally 
specific factors in our models. For example, physician- 
level factors such as age, years in practice, and the 
awareness of and attitude toward clinical guidelines and 
recommendations vary across physicians and could affect 
the communication with patients and finally the patients’ 
behaviors.49 In addition, some patient- level characteris-
tics were not captured in our data source, for example, 
educational level or marital status, as well as patients’ 
preferences, which were demonstrated to be potentially 
related to the utilization of healthcare services.40 By 
mapping out the unexplained spatial variation, we noted 
that the spatial patterns of regional variation were incon-
sistent across the four measures studied. These patterns 
indicated that the utilization of the four measures 
strongly recommended to patients with diabetes differ 
substantially within Switzerland. The spatial variation of 
utilization might be even less prominent after controlling 
for more potentially influential factors unmeasured in 
the present study, such as physician characteristics which 
could not be captured from the claims data. Combina-
tion of different data sources may serve as a promising 
approach in future studies.
In addition to the limitations mentioned above, further 
potential weaknesses should be noted about this study. 
First, the health insurance claims data have limited clin-
ical information; for example, outpatient diagnoses are 
lacking. The study population was selected according 
to the prescription of any diabetes medication, which 
may have led to some misclassification of prevalent and 
incident cases; this might partially account for the unex-
pected finding of more utilization of LDL testing in inci-
dent patients. It was impossible to distinguish between 
type 1 and type 2 diabetes. Patients with type 1 diabetes 
are a small fraction (approximately 8% in Switzerland 
in 201450); they normally get the illness when they are 
young, tend to be well treated by specialists, and are 
generally better at self- management. Due to the high costs 
of insulin injections and the associated medical supplies 
and devices, choosing a low deductible level is expected 
in patients with type 1 diabetes. Such different behaviors 
may have had an impact on utilization of the four measures 
and influenced our results to a certain degree. Besides, 
the laboratory test results were not available from claims 
data and it was impossible to estimate the proportion of 
targets achieved for the diabetes management measures. 
Second, we used claims data from a single health insurer. 
Enrollees of other health insurers might theoretically 
have different characteristics and show different health-
care use patterns. However, the results presented were 
based on a population of 1.2 million covering all regions 
in Switzerland. The benefit package of the mandatory 
health insurance is defined at the federal level and is the 
same for all health insurers. Thus, we expect little devia-
tion of enrollees’ features compared with the total Swiss 
population, and the results should be generalizable to 
the whole of Switzerland.
In conclusion, we observed that the utilization of 
four diabetes management measures was not optimal in 
Switzerland although these measures have been recom-
mended broadly and are based on strong evidence. 
Sociodemographics, health insurance preferences, and 
clinical characteristics were associated with their utiliza-
tion. The presence of supplementary insurance, a lower 
deductible level, and participation in a managed care 
plan were associated with higher utilization, consistently 
across the four measures. After controlling for available 
factors and spatial autocorrelation, maps of remaining 
variation indicated inconsistent patterns of utilization in 
the four measures. Our findings indicate that the uptake 
of strongly recommended measures for diabetes manage-
ment could possibly be optimized by providing further 
incentives to insured and care providers through insur-
ance scheme design. By contrast, due to the absence of 
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marked regional variation patterns, we conclude that 
there may be only limited potential for improvement 
by targeted regional intervention (eg, awareness and 
promotion campaigns). Moreover, our novel approach 
aids in the identification of geographic variation and 
influencing factors of healthcare services use in Switzer-
land and comparable settings worldwide.
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